For more than a decade, doctors have had a drug that can slash LDL cholesterol by more than half and demonstrably reduce heart attacks and strokes. For most of that decade, they have been saving it almost exclusively for patients who already have established cardiovascular disease — people who have already had a heart attack, already been diagnosed with atherosclerosis. That is the standard of care. That is what the guidelines say.
A new analysis published in JAMA this week, first flagged by ScienceDaily, suggests the guidelines may have been leaving a large and vulnerable group behind.
The VESALIUS-CV trial, a large cardiovascular outcomes study of evolocumab (Repatha, Amgen), included a prespecified subgroup of 3,655 patients with diabetes but no known significant atherosclerosis. In this population — people who had never been diagnosed with heart disease but carried elevated cardiovascular risk by virtue of their diabetes — evolocumab reduced the combined rate of heart attack, stroke, and coronary death by 31 percent compared with statin therapy alone, according to the JAMA paper led by Nicholas A. Marston, a preventive cardiologist at Brigham and Women's Hospital in Boston. The absolute numbers tell a more measured story: 5 percent of evolocumab-treated patients experienced a major cardiovascular event over five years, versus 7.1 percent on statins alone. That is a 2.1 percentage-point difference — meaningful, but not dramatic on its face.
What makes this result significant is where it sits relative to clinical convention. PCSK9 inhibitors like evolocumab have been approved since 2015. They are among the most potent LDL-lowering drugs available, driving median LDL from 121 mg/dL at baseline down to 52 mg/dL at 48 weeks in this subgroup. The cholesterol-lowering story is settled — what has always been contested is who should get them and when.
The current 2026 ACC/AHA dyslipidemia guidelines, released just last week, recommend an LDL target of less than 100 mg/dL for diabetics without clinical atherosclerotic cardiovascular disease, and less than 70 mg/dL for those with multiple risk factors. But PCSK9 inhibitors remain absent from primary prevention recommendations entirely. They are reserved for high-risk patients with established ASCVD who are already on maximally tolerated statin therapy. The evidence gap that VESALIUS-CV's diabetic subgroup now partially fills is not small: this is a population that cardiologists describe as high-risk, often managed by endocrinologists or primary care physicians rather than in cardiology clinics, and systematically undertreated with the most potent lipid-lowering tools available.
"PCSK9 inhibitors have been approved now for 11 years, and we just haven't seen the uptake throughout medical practice," Marston told TCTMD, which first reported on the data from the ACC 2026 Scientific Session. "I hope that with this analysis we can really message the importance of PCSK9 inhibitor use out to community primary care and other specialties."
The mortality signal in the data is worth noting even though it was not the primary endpoint. Patients randomized to evolocumab showed a 24 percent relative reduction in all-cause mortality over the trial period — 7.8 percent versus 10.1 percent at five years — a difference the authors flagged as consistent with what the Cholesterol Treatment Trialists Collaboration meta-regression would have predicted. The editorial accompanying the paper, by Philip Greenland and Donald M. Lloyd-Jones of Northwestern and published by the ACC, calls the results "benefit in a high-risk primary prevention patient population" while flagging open questions about long-term outcomes, cost-effectiveness, and the appropriate age and risk threshold for initiating therapy in younger, lower-risk patients. Those are not dismissals — they are the exact questions that guideline committees ask before they change practice.
The cost-effectiveness question is a real one. PCSK9 inhibitors are expensive — list prices run to thousands of dollars per year — and the absolute benefit in primary prevention, while consistent with the class effect, is smaller in absolute terms than in the secondary prevention patients where these drugs are already established. Karen Aspry, a cardiologist at Brown University, noted at the ACC briefing that ezetimibe, a cheaper LDL-lowering agent, is a more cost-effective intermediate step before escalating to PCSK9 inhibition. That argument has not gone away.
What may shift the calculus is payer coverage. John D. Bucheit, a pharmacist and member of the ACC's Prevention Council, said at the same briefing that he is hopeful the new data will improve payer coverage for PCSK9 inhibitors in high-risk primary prevention. If insurers expand access, the incentive calculus for cardiologists and primary care physicians to prescribe these drugs in diabetic patients before disease is established changes. Right now, the prior authorization burden is significant enough that many clinicians default to high-intensity statins alone even when guidelines and clinical judgment point toward additional therapy.
The VESALIUS-CV trial enrolled its first patient in June 2019 and completed last patient visit in July 2025, with a median follow-up of 4.8 years. The main results, published in JAMA in late 2025, showed evolocumab reduced major cardiovascular events in the overall high-risk population. The diabetic primary-prevention subgroup analysis — the result in hand now — was prespecified and sufficiently powered to detect the observed effect size. That matters: this is not a post-hoc fishing expedition. It is the trial the investigators said they were running.
Whether this subgroup result moves guidelines depends on factors beyond the data. The 2026 guidelines were already finalized when the main VESALIUS-CV results were published, though the writing committee acknowledged in an editorial that the trial provided evidence for more-intensive LDL targets in high-risk diabetics. The next iteration of guidelines will need to grapple with a trial that says, in effect: the people we have been excluding from PCSK9 inhibitor therapy are the people who appear to benefit from it. That is not a small thing to reconcile.
The deeper story here is not that a drug works. It is that the system has spent eleven years not using a drug that works, for a population that is easy to underestimate. Diabetics without established atherosclerosis do not show up in cardiology clinics. They are not the dramatic STEMI patients. They are, in Marston's phrase, "high-risk patients with diabetes" managed upstream — and apparently undertreated — by everyone else. VESALIUS-CV is now a reason to look upstream.
The next thing to watch is whether guideline committees reconvene to incorporate this data, and whether the payer landscape follows. The drug works. The question has never been the drug. It is who gets it, who pays for it, and whether medicine can move fast enough to use what it already has.
